StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30144% above fair value
$170.29−2.38 (-1.38%)

Close on Nov 19, 2026Market cap $10.89BP/E –Yield –

Repligen pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Repligen's pe ratio was 234.5× on Nov 11, 2026, against 889.8× a year earlier. Over the last 5 years it ranged from 45.3× to 889.8×, with a median of 136.4×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026234.5×−557.1
2024Oct 31, 2024791.6×+692.1
2023Dec 29, 202399.5×+43.0
2022Dec 30, 202256.5×−69.6
2021Dec 31, 2021126.1×−107.6
2020Dec 31, 2020233.7×+44.9
2019Dec 31, 2019188.8×+85.4
2018Dec 31, 2018103.4×+41.9
2017Dec 29, 201761.5×−92.6
2016Dec 30, 2016154.1×+49.3
2015Dec 31, 2015104.8×+49.8
2014Dec 31, 201455.0×–

More Repligen figures

See a number that looks wrong?